Clinical trials carried out to assess non-parenteral routes for administration of Wistar RA 27/3 strain live attenuated rubella vaccine.
The problems encountered in obtaining acceptable seroconversion rates following intranasal and buccal administration of Wistar RA 27/3 strain live attenuated rubella vaccine are discussed with reference to vaccination technique, virus dose and other factors. Results from buccal administration of vaccine were not encouraging. However, intranasal vaccination may be acceptable if devices can be developed for the administration of vaccine which give reproducible sero-conversion rates equivalent to those obtained by subcutaneous vaccination.